Tim Knotnerus (file photo)
AgomAb Therapeutics looks to take its 'true MET agonist' for broad use into the clinic with $74M round
Years ago, argenx reached out to Paolo Michieli, an Italian professor at the University of Torino. They wanted an expert’s help finding MET antagonists, and Michieli — who has spent more than two decades researching the biology of hepatocyte growth factor — was their guy.
What they discovered along the way was a series of agonists, which formed the basis for AgomAb Therapeutics’ launch in 2017. And on Wednesday, the team unveiled a $74 million Series B round to fund proof-of-concept studies for their lead candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
